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Abstract
To evaluate the clinical reliability of two rapid inﬂuenza detec-
tion tests (RIDTs), we analyzed 107 specimens from patients
with clinically suspected pandemic inﬂuenza A/H1N1v by these
tests as well as by real-time PCR as a standard. Both RIDTs had
a moderate sensitivity (28–32%), a high speciﬁcity (93–99%) and
a negative predictive value of 80%. These results will impact on
the clinical management and isolation precautions in patients
with suspected infection. Although a positive RITD is mostly
conﬁrmatory, a negative result in the presence of high clinical
likelihood of infection should be interpreted with caution and be
re-evaluated by PCR.
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During the outbreak of the pandemic inﬂuenza A (H1N1v) in
2009, tests for rapid detection of inﬂuenza antigens (RIDT)
were widely recommended and widely used as bedside
screening for inﬂuenza in suspected patients. These tests had
a high predicted sensitivity, which made them attractive as a
clinical screening test [1,2]. However, the parallel testing of
such patients by means of real-time PCR from the same
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nasal or pharyngeal swabs used for RIDT indicated that the
sensitivity of the RIDT might be lower. This is a serious
concern because the rapid diagnosis of infection with
H1N1v is important for preventing the further spread of
the disease. Because the symptoms of the infection with
the pandemic inﬂuenza virus are variable [3,4], the availabil-
ity of reliable rapid bedside tests is relevant for guiding the
clinical management of patients in terms of transmission of
the infection. Thus, as an initial assessment, several test
methods were investigated and compared for their ability
to detect H1N1 viral antigens in respiratory clinical speci-
mens by the CDC [5–8]. The results obtained indicated
that the RIDTs were capable of detecting novel inﬂuenza A
(H1N1v) virus from respiratory specimens containing high
levels of virus with a varying sensitivity (40–69%) [5]. With
the epidemiologic spread of novel inﬂuenza, conﬁrmatory
tests for the diagnosis of H1N1v infection by real-time
PCR were introduced [9,10]. We thus studied the accuracy
of two available RIDTs in comparison with real-time PCR
for H1N1v.
One hundred and seven specimens of nasal or pharyngeal
swabs were obtained from patients with inﬂuenza-like symp-
toms presenting at the Department of Internal Medicine,
University Hospital of Innsbruck, Austria. Swabs were eluted
in 500 lL of transport medium: 100 lL of the elution were
used for the rapid antigen tests and the remaining 300 lL
were used for performance of real-time PCR for H1N1v. Of
these specimens 107 were tested with BinaxNow Inﬂuenza
A&B Rapid Test (Inverness Medical, Cologne, Germany)
[8,11–13] and 96 in parallel with BD Directigen EZ Flu A&B
test (Becton& Dickinson, Sparks, MD, USA) [8] in accor-
dance with the manufacturer’s instructions. Results were cat-
egorized as either negative, weakly positive or positive. For
calculation, weak bands in the test ﬁeld were deﬁned as posi-
tive. In ﬁve patients, swabs were taken on two consecutive
days because of a strong suspicion of inﬂuenza despite an
initial negative rapid antigen test result.
TaqMan real-time PCR targeting the haemagglutinin (HA)
genes of porcine inﬂuenza A/H1N1v virus was established and
performed as described previously [14]. The primers and
probe used were: FluSw H1 F236 (TgggAAATCCAgAgTg
TgAATCACT) as sense primer, FluSwH1 R318 (CgTTCCA
TTgTCTgAACTAgRTgTT) as antisense primer and Flu Sw H1
TM292 (FAM – CCACAATgTAggACCATgAgCTTgCTgT- B
BQ) as probe.
The diagnostic potential of the antigen tests was com-
pared with the results of the real-time PCR, which was set
as the standard. Statistics were calculated with SPSS statistical
software, version 11.5, for Windows (SPSS Inc., Chicago, IL,
USA).
Among the 107 clinical specimens, 29 were tested positive
for inﬂuenza A/H1N1v by real-time PCR. Using BinaxNOW
Inﬂuenza A&B rapid antigen test, nine of the 107 tested
specimens were also found positive, eight of which were
conﬁrmed by real-time PCR. Accordingly, in comparison with
the results of real-time PCR, one specimen in the rapid test
was classiﬁed as false positive, whereas 21 were found to be
false negative.
With the BD Directigen EZ Flu A&B rapid antigen test, 13
specimens out of 96 gave positive results and, according to
the results of the real-time PCR, eight were classiﬁed as true
positives, whereas ﬁve were false positives, and, in addition,
17 rapid antigen tests provided false negative results. Thus,
both RIDTs had a low sensitivity (32% for BD Directigen EZ
Flu A&B vs. 27.6% for BinaxNow Inﬂuenza A&B). However,
both tests revealed a high speciﬁcity (98.7% for BinaxNow
Inﬂuenza A&B and 93% for BD Directigen EZ Flu A&B),
which is in line with the ﬁndings of the CDC. Subjects with a
positive result in the BD Directigen EZ Flu A&B were more
likely to lack conﬁrmation of infection than with the Binax-
Now Inﬂuenza A&B assay (positive predictive value 88.9%
for BinaxNOW Inﬂuenza A&B vs. 61.5% for BD Directigen
EZ Flu A&B). Both assays displayed similar negative predic-
tive values (78.6% for BinaxNOW Inﬂuenza A&B and 79.5%
for BD Directigen EZ Flu A&B). Disease prevalence for pan-
demic inﬂuenza was 26% for all samples performed with the
BD Directigen EZ Flu A&B and 27% for samples evaluated
with BinaxNOW Inﬂuenza A&B.
Because there was no background of seasonal inﬂuenza A
or B at the time of the present study, cross reactions of
RIDTs with ‘seasonal’ inﬂuenza are unlikely to explain the
low rate of false positive results (false positive rate 1% for
BinaxNOW Inﬂuenza A&B and 5% for BD Directigen EZ Flu
A&B). In ﬁve patients, a second clinical specimen was
obtained, 1 or 2 days after the ﬁrst test because of primary
negative testing in the presence of a high suspicion of
H1N1v infection. Two of the consecutive tests were classi-
ﬁed as positive by the BinaxNow Inﬂuenza A&B assay (one
false and one true positive according to real-time PCR),
whereas three clinical swab eluents turned positive with the
BD Directigen EZ Flu A&B test (one true positive and two
false positives).
Our investigations of rapid antigen inﬂuenza tests during
pandemic inﬂuenza A/H1N1v conﬁrm the high speciﬁcity of
each RIDT but a signiﬁcant lack of sensitivity [15,16]. How-
ever, the results obtained indicate a better sensitivity for the
BinaxNow Inﬂuenza A&B antigen test than that recently
described by Drexler et al. [17] who calculated a sensitivity of
11.1% during the 2009 pandemic season. This low sensitivity
refers to a high percentage of children among the investigated
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patients and a lack of test sensitivity for inﬂuenza A/H1N1v
[17]. However, in the present study, we only investigated
adults and the diagnostic workup for antigen testing and PCR
were performed using the same specimen, ruling out that any
differences in obtaining nasal or pharyngeal swabs are respon-
sible for the low sensitivity of the rapid test observed.
Accordingly, a deﬁnitive diagnosis of infection with inﬂuenza
A/H1N1 virus requires real-time PCR analysis [10] in patients
who test negative with RIDT, whereas a positive RIDT is con-
ﬁrmatory for infection with inﬂuenza A/H1N1v, and does not
require conﬁrmation by real-time PCR analysis. Rapid antigen
tests have decreased sensitivity for detecting pandemic inﬂu-
enza A/H1N1v compared to seasonal inﬂuenza A subtypes
[18]. However, many primary health centres do not have
access to real-time PCR to allow the re-evaluation of test
results in patients with a high suspicion of infection but a neg-
ative RIDT. Thus, point of care strategies that allow practitio-
ners rapid access to laboratories providing continuous
reception/processing of samples and a reduction in the time
needed to provide consolidated results have both proven
helpful for the clinical management of pandemic inﬂuenza [2].
However, it appears that the sensitivity of the tests is lower
than expected, which could be a reﬂection of low viral load in
an early stage of the infection, comprising an argument in
favour of repeated testing.
Moreover, enrichment of the viral concentration in the
specimen by reducing the volume of the elution medium
may improve the sensitivity of RIDTs. Improvements of the
test and/or the specimen sampling procedure are manda-
tory for increasing the sensitivity of rapid tests that are
clinically useful during the onset of a new pandemic wave
of inﬂuenza infection. The results of the present study will
impact on the clinical management and isolation precautions
in patients with suspected pandemic inﬂuenza infection. On
the basis of our observations, patients with a high clinical
suspicion for infection with inﬂuenza A/H1N1v but a nega-
tive rapid antigen test should be considered positive until
the results of the real-time PCR become available, whereas
a positive result does not require conﬁrmation by real-time
PCR. An accurate and timely diagnosis can provide informa-
tion that is useful for the appropriate treatment and care
of the patient, as well as for the implementation of preven-
tion measures against the spread of inﬂuenza to other
patients [19].
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